EuroBiotech: More Articles of Note


> Galapagos wrapped up two moves that significantly increased its spending power. First, the biotech completed a €363.9 million ($395.2 million) financing, adding to the €973 million it had in the bank at the end of last year. Then, shareholders voted to allow Galapagos management to increase its share capital by 33% without first seeking their permission. Galapagos tried to gain such flexibility last year but was knocked back by investors. The management team’s success at the second time of asking means it now has the firepower to pull off a head-turning acquisition. Statement I De Tijd (Dutch)

> Transgene and Bristol-Myers Squibb agreed to test their drugs in combination. Bristol-Myers will provide one its checkpoint inhibitor Opdivo for use in a Transgene-sponsored trial. Transgene wants to assess the effect of the anti-PD-1 monoclonal antibody in combination with its therapeutic vaccine TG4010. The phase 2 trial will give the combination as a first-line treatment to patients with advanced non-squamous non-small cell lung cancer who have low levels of PD-L1. Release

> Kiadis Pharma filed for approval of ATIR101 in Europe. The Dutch biotech is seeking approval as an adjunctive treatment in haematopoietic stem cell transplantation for malignant disease. Kiadis made the filing after discussing data from a phase 2 trial of the adjunctive immunotherapeutic with regulators. Statement

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> ObsEva began a phase 3 program for OBE2109 in patients with uterine fibroids. The late-phase program for the gonadotropin-releasing hormone receptor antagonist consists of two phase 3 trials that will enroll 1,000 patients across 200 sites. Release

> Pfizer struck a deal with Domain Therapeutics. The agreement will see Domain use its bioSensAll technology to look at the effect of mutations on signaling pathways engaged by G protein-coupled receptors. Statement

> The European Medicines Agency added uniQure’s hemophilia B gene therapy to its PRIME scheme. PRIME status positions uniQure to receive regulatory support and fast-tracked processes as it develops AMT-060. Release